- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03530332
Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)
Prediction and Prevention of Preterm Birth: A Prospective, Randomized Intervention Trial
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Preterm birth (PTB) remains the leading cause of neonatal mortality and long-term disability throughout the world. Recently treatments early in pregnancy such as progesterone, cervical support and maternal support have been demonstrated to delay delivery amongst at risk women. Nonetheless, the majority of women who are at risk are not identified using current screening methods.
Women who are 18 years or older, with a singleton pregnancy between 19 5/7 weeks and 20 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment and no history of prior preterm birth (delivery between 16 0/7 weeks and 37 6/7 weeks) will be invited to participate. Women who enroll will be randomized to screening and intervention for those at high risk of PTB or no screening and standard care. All participants will undergo sample collection, but the samples from the group randomized to "no screening' will not be analyzed until the end of the study (post-delivery of all neonates).
Women randomized to the intervention group will be screened using the PreTRM® test (Sera Prognostics, Inc.) at a large tertiary care center. Predicated upon the degree of risk, women will be treated according to a pre-specified algorithm. The outcomes of these women will be compared to a control group of women who do not receive screening at the same tertiary care center.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Utah
-
Murray, Utah, Estados Unidos, 84107
- Intermountain Medical Center
-
Ogden, Utah, Estados Unidos, 84403
- McKay-Dee Hospital
-
Provo, Utah, Estados Unidos, 84604
- Utah Valley Hospital
-
Salt Lake City, Utah, Estados Unidos, 84143
- LDS Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
- Subject is greater than or equal to 18 years of age AND
- Uncomplicated singleton intrauterine pregnancy less than 21 weeks estimated gestation AND
- No medical contraindications to continuing pregnancy AND
- No previous classical cesarean section AND
- No known uterine anomaly AND
- No history of cervical conization AND
- No plan for cesarean section prior to 37 0/7 weeks gestation AND
- No plan for induction of labor prior to 37 0/7 weeks gestation AND
- Subject has no history of spontaneous preterm delivery AND
- No prior PPROM less than 34 weeks AND
- Subject has no signs and/or symptoms of preterm labor AND
- Subject has intact membranes AND
- Subject has not received a blood transfusion during the current pregnancy.
Exclusion Criteria
- Subjects who have taken or plan to take progesterone beyond 13 6/7 weeks gestation prior to study enrollment OR
- Any other medical conditions that put subject at increased risk of preterm birth in the judgment of the site investigator OR
- The subject has a planned cerclage placement for the current pregnancy OR
- Previously identified short cervix (less than 2.5 cm by transvaginal ultrasound) prior to enrollment OR
- Known major structural fetal anomalies that may shorten pregnancy (e.g., anencephaly, holoprosencephaly, schizencephaly, gastroschisis, omphalocele, congenital diaphragmatic hernia) OR
- Known fetal genetic anomalies that are incompatible with life (e.g., trisomy 13 or trisomy 18) OR
- The subject has known elevated bilirubin levels (hyperbilirubinemia) OR
- The subject has taken or plans to take any of the following medications after the first day of the last menstrual period: Enoxaparin, heparin, heparin sodium, low molecular weight heparin, low dose aspirin OR
- A history of allergic reaction to aspirin or 17-OHPC injections OR
- Subject does not plan to deliver at an Intermountain Healthcare hospital.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Control
|
|
|
Experimental: Tratamiento
|
Blood test to determine risk of preterm birth
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Incidence of spontaneous preterm birth
Periodo de tiempo: Before 37 weeks of pregnancy
|
Before 37 weeks of pregnancy
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Edad gestacional al momento del parto
Periodo de tiempo: A la entrega
|
A la entrega
|
|
Neonatal Intensive Care Unit (NICU) length of stay only among neonates who were admitted to the NICU
Periodo de tiempo: Up to 1 year post delivery
|
Up to 1 year post delivery
|
|
Length of stay among all neonates (including NICU and nursery)
Periodo de tiempo: Up to 1 year post delivery
|
Up to 1 year post delivery
|
|
Neonatal costs
Periodo de tiempo: Up to 1 year post delivery
|
Up to 1 year post delivery
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ware Branch, M.D., Intermountain Health Care, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PREVENT-PTB Protocol 1.02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .